Moderna Inc. (MRNA) stock plummeted 5.01% in the intraday trading session on Tuesday, as the biotechnology company announced a significant downward revision to its 2025 sales guidance, citing challenges with its product pipeline and increasing competition.

The company now expects total revenues in the range of $1.5 billion to $2.5 billion for 2025, marking a substantial reduction of $1 billion from its previous guidance. This revised forecast fell well below Wall Street analysts' expectations, which had anticipated revenues of around $2.94 billion for the year.

Moderna attributed the guidance cut to several factors, including lower-than-expected sales of its COVID-19 vaccine and the anticipated launch of its next-generation vaccine candidate, mRNA-1283, which is awaiting regulatory approval. Additionally, the company faced a setback with its cytomegalovirus (CMV) vaccine candidate, as an independent data monitoring committee recommended continuing the late-stage CMVictory study, indicating that the vaccine did not meet the criteria for early efficacy.